WuXi Biologics

Shanghai, CN · Wuxi, CN
Find alternatives to WuXi Biologics for CAR-T →
CAR-T Cell Therapy AAV ADC Monoclonal Antibody
Program data pending ClinicalTrials.gov matching · Last scored 2026-10-29
82.7
Signal Score
✓ FDA Inspections (1) ○ Clinical Trials ○ SEC Filings ✓ Press (20) ✓ EMA GMP (3) ✓ MHRA GMP (1) ✓ HC GMP (2)

Quick Facts: WuXi Biologics

Signal Score
82.7/100 (as of 2026-10-29)
Quality Compliance
99.6/100 — Clean EMA record: 3 active GMP certificates (no deductions)
Headquarters
Shanghai, CN · Wuxi, CN
Modalities
CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About WuXi Biologics

Pure-play CDMO.

Signal Score & Pillar Breakdown

Quality Compliance 99.6
Clean EMA record: 3 active GMP certificates (no deductions)
Sources: FDA Data Dashboard, EMA EudraGMDP, MHRA GMDP
Clean EMA record: 3 active GMP certificates (no deductions)
FDA Inspections1 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2026-07-03)
EMA GMP Certificates3 on record
MHRA GMP Certificates1 on record
Most Recent HC OutcomeCompliant · 2024-10-11
HC Attribution2 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Clean EMA record: 3 active GMP certificates (no deductions)
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability 68.0
Parent company: WuXi AppTec
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: WuXi AppTec
Financial assessment: 68.0/100
Capacity 68.0
3 manufacturing sites
Broad modality coverage (5 modalities)
Sites: Shanghai, CN, Wuxi, CN, Dundalk, IE
Source: company profiles (manufacturing sites, modality breadth)
3 manufacturing sites
Press Signals20 articles (not scored)
3 manufacturing sites
Broad modality coverage (5 modalities)

WuXi Biologics FDA Inspection History

2026-07
NAI VAI OAI
Date Site Type 483 citations posted Classification
2026-07-03
Wuxi Biologics Co Ltd
Wuxi Company-level
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
Source: FDA Data Dashboard · Retrieved Nov 21, 2026

WuXi Biologics EMA GMP Compliance 3 certificates

2024-10
2024-10
2024-08
Compliant Non-Compliant
Certificate Site Country Inspection Date Status
35282/IMP13104/00001 Wuxi Biologics Ireland Limited Ireland 2024-10-11 COMPLIANT
35282/M13105/00001 Wuxi Biologics Ireland Limited Ireland 2024-10-11 COMPLIANT
DE_NW_03_GMP_2025_0079 WuXi Biologics Germany GmbH Germany 2024-08-23 COMPLIANT
Source: EMA EudraGMDP · Retrieved Nov 21, 2026

WuXi Biologics MHRA GMP Compliance 1 certificates

2025-08
Compliant Non-Compliant
Certificate Site City / Postcode Inspection Date Status
UK GMP 52290 Insp GMP 52290/19113162-0001[H] WUXI BIOLOGICS CO LIMITED CN-214092 2025-08-12 COMPLIANT
Source: MHRA GMDP Database · Retrieved Nov 21, 2026

Japan-accredited overseas site (PMDA)

biologics · 2 sites

  • Wuxi, China · WuXi Biologics Co., Ltd. — biologics · valid to Jul 30, 2031
  • Dundalk, Ireland · WuXi Biologics Ireland Limited — biologics · valid to May 27, 2031

PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)

Hiring Activity Beta

Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data. This company's careers site asks automated readers not to collect it (robots.txt), and we respect that.
Source: public careers pages · Checked Nov 20, 2026

Company Signals 20 articles

Company announcements, not verified evidence. They do not change any score.
general 2026-10-25
WuXi Biologics breaks ground on CRDMO center in Singapore - Singapore Economic Development Board (EDB)
WuXi Biologics breaks ground on CRDMO center in Singapore  Singapore Economic Development Board (EDB)
general 2026-10-25
What WuXi Biologics Buyers Were Betting On - Simply Wall Street
What WuXi Biologics Buyers Were Betting On  Simply Wall Street
general 2026-10-19
WuXi Biologics at Festival of Biologics Basel 2026: Turning Scientific Complexity Into Commercial Certainty - Moomoo
WuXi Biologics at Festival of Biologics Basel 2026: Turning Scientific Complexity Into Commercial Certainty  Moomoo
regulatory 2026-10-14
WuXi Biologics Continues to Be Included in Multiple Hang Seng Sustainability Indexes, Demonstrating ESG Excellence - PR Newswire
WuXi Biologics Continues to Be Included in Multiple Hang Seng Sustainability Indexes, Demonstrating ESG Excellence  PR Newswire
general 2026-10-09
WuXi Biologics at CPHI Milan 2026: Empowering Biomanufacturing in Europe - PR Newswire
WuXi Biologics at CPHI Milan 2026: Empowering Biomanufacturing in Europe  PR Newswire
regulatory 2026-10-06
How FDA Inspection Success At WuXi Biologics Stock Has Changed Its Investment Story - Simply Wall Street
How FDA Inspection Success At WuXi Biologics Stock Has Changed Its Investment Story  Simply Wall Street
general 2026-04-29
WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access - The Manila Times
WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access  The Manila Times
general 2026-04-28
Assessing WuXi Biologics (SEHK:2269) Valuation As Undervaluation Narrative Gains Traction - simplywall.st
Assessing WuXi Biologics (SEHK:2269) Valuation As Undervaluation Narrative Gains Traction  simplywall.st
general 2026-04-28
Assessing WuXi Biologics (SEHK:2269) Valuation As Undervaluation Narrative Gains Traction - simplywall.st
Assessing WuXi Biologics (SEHK:2269) Valuation As Undervaluation Narrative Gains Traction  simplywall.st
regulatory 2026-04-25
WuXi Biologics Secures MFDS GMP Certification For Three Key Manufacturing Facilities - BioPharma APAC
WuXi Biologics Secures MFDS GMP Certification For Three Key Manufacturing Facilities  BioPharma APAC
general 2026-04-24
WuXi Biologics Completes Structure of Chengdu Microbial Manufacturing Site - Contract Pharma
WuXi Biologics Completes Structure of Chengdu Microbial Manufacturing Site  Contract Pharma
general 2026-04-24
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival - Yahoo! Finance Canada
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival  Yahoo! Finance Canada
general 2026-04-24
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival - Yahoo Finance
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival  Yahoo Finance
general 2026-04-24
WuXi Biologics Achieves Structural Completion and Key Equipment Arrival At Chengdu Microbial Commercial Manufacturing Site - marketscreener.com
WuXi Biologics Achieves Structural Completion and Key Equipment Arrival At Chengdu Microbial Commercial Manufacturing Site  marketscreener.com
regulatory 2026-04-23
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics - Eastern Progress
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics  Eastern Progress
regulatory 2026-04-23
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics - marketscreener.com
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics  marketscreener.com
regulatory 2026-04-23
WuXi Biologics Secures MFDS GMP Certification For Three Key Manufacturing Facilities - BioPharma APAC
WuXi Biologics Secures MFDS GMP Certification For Three Key Manufacturing Facilities  BioPharma APAC
regulatory 2026-04-23
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics - The Manila Times
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics  The Manila Times
regulatory 2026-04-23
WuXi Biologics Secures MFDS GMP Certification For Three Key Manufacturing Facilities - BioPharma APAC
WuXi Biologics Secures MFDS GMP Certification For Three Key Manufacturing Facilities  BioPharma APAC
regulatory 2026-04-23
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics - Yahoo Finance
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics  Yahoo Finance

Frequently Asked Questions About WuXi Biologics

How many FDA inspections does WuXi Biologics have on record?
CDMO Signal tracks 1 FDA inspection for WuXi Biologics, sourced from the FDA inspection database. See the full inspection history above.
Has WuXi Biologics received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for WuXi Biologics.
Does WuXi Biologics hold EMA or MHRA GMP certificates?
CDMO Signal tracks 3 EMA and 1 MHRA GMP certificates for WuXi Biologics.
What is WuXi Biologics's CDMO Signal Score?
WuXi Biologics has a Signal Score of 83/100, based on quality, operations, financial stability, and capacity data.
Evaluating WuXi Biologics for a manufacturing program?
Use the free AI matchmaker to compare WuXi Biologics against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs → AAV CDMOs → ADC CDMOs →

Similar CDMOs

AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 79.9
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
Lonza
Basel, Switzerland
Signal Score: 72.8
AAV, Lentiviral, Cell Therapy, mRNA, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation, Small Molecule API, High-Potency APIs, Oral Solid Dose
Rose BioSolutions
Rockville, MD · Memphis, TN · Keele, United Kingdom
Signal Score: 64.0
AAV, Lentiviral, Adenoviral, Plasmid, Cell Therapy, CAR-T
Catalent
Tampa, FL
Signal Score: 76.1
Monoclonal Antibody, Recombinant Protein, ADC, AAV, mRNA, Plasmid DNA, Fill-Finish

Compare WuXi Biologics with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on WuXi Biologics
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.